Current treatment standards and future strategies in mantle cell lymphoma

Annals of Oncology

Volumn 19, Issue SUPPL. 4, 2008, Pages

  Dreyling, M ^a   Weigert, O ^a   Hiddemann, W ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANTHRACYCLINE; BENDAMUSTINE; BORTEZOMIB; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EVEROLIMUS; FLAVOPIRIDOL; FLUDARABINE; IBRITUMOMAB TIUXETAN; LENALIDOMIDE; METHOTREXATE; MITOXANTRONE; PREDNISONE; RITUXIMAB; TEMSIROLIMUS; THALIDOMIDE; TOSITUMOMAB I 131; VINCRISTINE; ANTINEOPLASTIC AGENT;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 14; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DNA DAMAGE; DRUG MEGADOSE; GENE MUTATION; GRAFT VERSUS HOST REACTION; HUMAN; MANTLE CELL LYMPHOMA; MOLECULAR GENETICS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOTHERAPY; RISK FACTOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; DOSE RESPONSE; FORECASTING; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; STANDARD; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FORECASTING; HUMANS; IMMUNOTHERAPY; LYMPHOMA, MANTLE-CELL; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STEM CELL TRANSPLANTATION;

EID: 48149108610     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn193     Document Type: Article

References (16)

1. Rosenwald A, Wright G, Wiestner A et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3: 185-197.
2. Fernandez V, Hartmann E, Ott G et al. Pathogenesis of mantle-cell lymphoma: All oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 2005; 23: 6364-6369.
3. Tiemann M, Schrader C, Klapper W et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): A clinicopathological study from the European MCL Network. Br J Haematol 2005; 131: 29-38.
4. Hoster E, Dreyling M, Klapper W et al. A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma. Blood 2008; 111: 558-565.
5. Pott C, Schrader C, Gesk S et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts longterm remission in mantle cell lymphoma. Blood 2006; 107: 2271-2278.
6. Howard OM, Gribben JG, Neuberg DS et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288-1294.
7. Rummel MJ, Al-Batran SE, Kim SZ et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 3383-3389.
8. Lefrere F, Delmer A, Suzan F et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: A prospective study. Leukemia 2002; 16: 587-593.
9. Dreyling M, Lenz G, Hoster E et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network. Blood 2005; 105: 2677-2684.
10. Lenz G, Dreyling M, Hoster E et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984-1992.
11. Schulz H, Bohlius JF, Trelle S et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99: 706-714.
12. Romaguera JE, Fayad L, Rodriguez MA et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013-7023.
13. Fisher RI, Bernstein SH, Kahl BS et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867-4874.
14. Weigert O, Pastore A, Rieken M, Lang N, Hiddermann W, Dreyling M. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 2007; 21: 524-528.
15. Kaufmann H, Raderer M, Wohrer S et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004; 104: 2269-2271.
16. Witzig TE, Geyer SM, Ghobrial I et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347-5356.